Geode Capital Management LLC Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Geode Capital Management LLC grew its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 10.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,432,697 shares of the company’s stock after buying an additional 136,458 shares during the quarter. Geode Capital Management LLC owned 1.42% of Day One Biopharmaceuticals worth $19,961,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the business. FMR LLC increased its stake in Day One Biopharmaceuticals by 178.5% in the 3rd quarter. FMR LLC now owns 7,412,380 shares of the company’s stock worth $103,254,000 after buying an additional 4,750,936 shares during the period. Braidwell LP grew its stake in Day One Biopharmaceuticals by 60.5% in the 3rd quarter. Braidwell LP now owns 4,873,853 shares of the company’s stock worth $67,893,000 after acquiring an additional 1,837,949 shares in the last quarter. Deerfield Management Company L.P. Series C increased its position in shares of Day One Biopharmaceuticals by 65.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 2,923,137 shares of the company’s stock worth $40,281,000 after acquiring an additional 1,157,825 shares during the period. Vestal Point Capital LP lifted its holdings in shares of Day One Biopharmaceuticals by 100.0% in the 3rd quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company’s stock worth $34,825,000 after buying an additional 1,250,000 shares during the period. Finally, Janus Henderson Group PLC grew its holdings in Day One Biopharmaceuticals by 18.4% during the 3rd quarter. Janus Henderson Group PLC now owns 2,177,197 shares of the company’s stock worth $30,307,000 after acquiring an additional 337,928 shares in the last quarter. 87.95% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. TD Cowen raised shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. Finally, Needham & Company LLC restated a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $35.71.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $13.31, for a total value of $399,300.00. Following the completion of the transaction, the insider now owns 1,034,015 shares in the company, valued at approximately $13,762,739.65. This represents a 2.82 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last ninety days, insiders sold 51,745 shares of company stock valued at $748,567. 8.40% of the stock is owned by insiders.

Day One Biopharmaceuticals Stock Down 0.2 %

DAWN opened at $12.87 on Friday. The company has a market cap of $1.30 billion, a P/E ratio of -12.50 and a beta of -1.51. Day One Biopharmaceuticals, Inc. has a 52-week low of $11.94 and a 52-week high of $18.07. The firm’s 50-day moving average price is $13.86 and its 200-day moving average price is $14.02.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.58. The firm had revenue of $93.76 million during the quarter, compared to analysts’ expectations of $15.05 million. During the same quarter in the previous year, the business earned ($0.54) earnings per share. On average, research analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.88 EPS for the current fiscal year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.